RHHBY - Roche Holding AG

Other OTC - Other OTC Delayed Price. Currency in USD
29.47
+0.56 (+1.94%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close28.91
Open29.27
Bid0.00 x 0
Ask0.00 x 0
Day's Range29.25 - 29.51
52 Week Range26.30 - 32.42
Volume1,726,746
Avg. Volume1,425,773
Market Cap205.572B
Beta0.43
PE Ratio (TTM)23.28
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.08 (3.84%)
Ex-Dividend Date2018-03-15
1y Target EstN/A
Trade prices are not sourced from all markets
  • Reuters18 hours ago

    Swiss, German drugmakers join U.S. price freeze

    European drugmakers Roche , Bayer and Merck KGaA became the latest companies to freeze prices in the United States for the rest of 2018 following criticism by President Donald Trump over the cost of medicine. Roche did boost U.S. prices for nine key drugs by an average of 3 percent on July 1, but said it would hold off additional increases as discussions with the Trump administration continue over a longer-term solution to containing healthcare costs.

  • Roche Takes Drug-Price Posturing to New Heights
    Bloomberg19 hours ago

    Roche Takes Drug-Price Posturing to New Heights

    Pfizer Inc. started things off earlier this month by agreeing to roll back mid-year price hikes and delay them — for a few months. Similar efforts announced this week by Novartis AG and Merck & Co. arguably won’t be any more consequential. In a statement Friday, the Swiss pharmaceutical giant said it told the Health and Human Services Department on July 11 that it wouldn’t enact any more price hikes in 2018.

  • Roche Hiked Cancer-Drug Prices Before Pledge to Keep Them Flat
    Bloomberg21 hours ago

    Roche Hiked Cancer-Drug Prices Before Pledge to Keep Them Flat

    Like a growing number of its peers, Roche Holding AG pledged this week not to raise drug prices for the rest of the year. Roche gave the U.S. government its no-price-rises promise on July 11, the company said in a statement Friday. The health system also needs to focus on “long-term, system-wide solutions that lower costs,” Roche said.

  • Reuters21 hours ago

    Swiss, German drugmakers join U.S. price freeze

    European drugmakers Roche (ROG.S), Bayer (BAYGn.DE) and Merck KGaA (MRCG.DE) became the latest companies to freeze prices in the United States following criticism by the Trump administration of the cost of medicine. Roche, Bayer and Merck KGaA all said on Friday they would not seek to lift prices this year in the world's biggest drug market, following Novartis (NOVN.S), Pfizer (PFE.N) and U.S. drugmaker Merck (MRK.N) which had already announced similar moves.

  • Pharma Stock Roundup: JNJ & NVS' Q2 Earnings, FDA Approvals
    Zacks23 hours ago

    Pharma Stock Roundup: JNJ & NVS' Q2 Earnings, FDA Approvals

    J&J (JNJ) and Novartis (NVS) kick off earnings for pharma sector on a strong note. FDA approves J&J's latest HIV medicine and line extension of Pfizer's prostate cancer drug.

  • Reutersyesterday

    Roche gets breakthrough status for Alzheimer's test Elecsys

    The U.S. Food and Drug Administration has granted Roche an accelerated review for its Elecsys product used to diagnose Alzheimer's disease, the Swiss drugmaker said on Friday. The FDA gave breakthrough ...

  • Roche's Tecentriq Met Primary Goal in First-Line NSCLC Study
    Zacks2 days ago

    Roche's Tecentriq Met Primary Goal in First-Line NSCLC Study

    Roche's (RHHBY) late-stage lung cancer study on immuno-oncology drug, Tecentriq, meets its co-primary endpoint of progression-free survival (PFS).

  • How Celgene’s Abraxane and Otezla Are Positioned ahead of Q2 2018
    Market Realist2 days ago

    How Celgene’s Abraxane and Otezla Are Positioned ahead of Q2 2018

    Celgene’s (CELG) Abraxane reported revenue of $262 million in the first quarter, reflecting an ~11.0% YoY (year-over-year) rise. Abraxane’s sales grew 12.0% in the US market to reach $159.0 million. In the international market, its sales grew 9.6% to reach $103 million. Otezla and other drugs’ revenue trends

  • Roche's Tecentriq Gets Breakthrough Therapy Status for HCC
    Zacks3 days ago

    Roche's Tecentriq Gets Breakthrough Therapy Status for HCC

    The FDA grants breakthrough therapy designation to Roche's (RHHBY) key cancer drug, Tecentriq, in combination with Avastin for the first-line treatment of advanced HCC.

  • Reuters3 days ago

    Nikkei rises to more than 1-month high as exporters get boost from weak yen

    Japan's Nikkei share average soared to a more than one-month high on Wednesday morning as exporters such as automakers and technology firms got a boost after the dollar hit a six-month high against the ...

  • Benzinga4 days ago

    Benzinga's Daily Biotech Pulse: Bellicum CFO Resigns, Roche's Trial Meets Endpoints, Avid Bioservices Turns To Black In Q4

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 16) Arcus Biosciences Inc (NYSE: RCUS ) BioLife Solutions Inc (NASDAQ: ...

  • Roche's Flu Drug Meets Primary Endpoint in Phase III Study
    Zacks4 days ago

    Roche's Flu Drug Meets Primary Endpoint in Phase III Study

    Roche (RHHBY) announces that its antiviral candidate, baloxavir marboxil, met the primary endpoint in a phase III study in patients suffering from risk of complications from the flu.

  • Reuters4 days ago

    Roche touts new flu drug as Tamiflu suffers generics hit

    Swiss drugmaker Roche's hopes of recapturing lost ground in the generics-flooded influenza market got a boost after a late-stage study showed its new medicine reduced symptoms in people at high risk of complications. Some analysts, however, have only muted expectations for the drug, baloxavir marboxil, since previously published results showed modest benefit compared to Roche's older Tamiflu medicine that is already under pressure from cheaper copies. In severe flu outbreaks, millions of people can get sick, resulting in hospital treatment and potentially hundreds of thousands of deaths, in particular among older people or those with compromised immune systems.

  • AbbVie's Imbruvica Fails in Phase III Blood Cancer Study
    Zacks9 days ago

    AbbVie's Imbruvica Fails in Phase III Blood Cancer Study

    AbbVie's (ABBV) Imbruvica fails to meet the primary endpoint in a phase III study evaluating the drug in patients with DLBCL, a rare blood cancer, who have received no prior treatment.

  • Celgene Reports Positive Data on Tecentriq, Abraxane Study
    Zacks10 days ago

    Celgene Reports Positive Data on Tecentriq, Abraxane Study

    Celgene (CELG) reports positive results from a late-stage study on the combination of oncology drug, Abraxane, with immuno-oncology drug, Tecentriq, in advanced breast cancer patients.

  • Dying to Survive, China Shows the Way on Drug Prices
    Bloomberg10 days ago

    Dying to Survive, China Shows the Way on Drug Prices

    U.S. President Donald Trump exulted this week over Pfizer Inc.’s decision to delay planned drug price increases a day after he attacked the company on Twitter. He should take a look at China, where President Xi Jinping has done much better.

  • Moody's10 days ago

    Moody's: European pharma sector earnings poised to rise into 2019 as new drugs come to market

    An emerging wave of blockbuster drugs will accelerate European pharmaceutical companies' revenue growth into 2019, says Moody's Investors Service in a report published today. The rating agency's report is an update to the markets and does not constitute a rating action.

  • Drugmakers Cancel Price Hikes After California Law Takes Effect
    Bloomberg11 days ago

    Drugmakers Cancel Price Hikes After California Law Takes Effect

    A handful of the world’s biggest drugmakers are canceling or reducing planned price increases in the U.S., following a new California drug pricing transparency law and continued political pressure over pharmaceutical costs. The California law, which began to take effect earlier this year, requires drugmakers to give insurers, governments and drug purchasers advance notice of large price increases, as a way of publicly pressuring pharmaceutical companies to keep prices down. In the past three weeks, Novartis AG, Gilead Sciences Inc., Roche Holding AG and Novo Nordisk A/S sent notices to California health plans rescinding or reducing previously announced price hikes on at least 10 drugs.

  • Financial Times12 days ago

    [$$] China vows to accelerate cancer drug price cuts

    China has vowed to speed up cuts to the cost of cancer drugs in a move that threatens to dent revenues in the country for multinationals such as Eli Lilly, Roche and Novartis. Officials will “accelerate price cuts” for cancer treatments, the Communist party-run People’s Daily reported over the weekend.

  • Morningstar12 days ago

    Biogen Scores Surprise Win

     Biogen BIIB and partner Eisai announced that amyloid antibody BAN2401 has yielded positive data in a large Phase 2 study in Alzheimer's disease. Biogen's strategy has its roots in the 2003 merger of Biogen (multiple sclerosis drug Avonex) and Idec (cancer drug Rituxan).

  • Alzheimer's Research Gets Glimmer of Hope, Not for First Time
    Bloomberg15 days ago

    Alzheimer's Research Gets Glimmer of Hope, Not for First Time

    For the few drugmakers that haven’t given up on the decades-long, elusive quest for a cure of Alzheimer’s disease, each piece of news is a small signpost along a possible path to success -- and billions of dollars in potential sales. This is the story of Alzheimer’s. Dramatic ups and downs have been typical, with about 200 failed attempts to find a treatment. Drugmakers are seeking to escape a maze, trying one approach, failing, then starting over with another.

  • Should Value Investors Consider Roche Holding (RHHBY) Stock?
    Zacks16 days ago

    Should Value Investors Consider Roche Holding (RHHBY) Stock?

    Let's put Roche Holding (RHHBY) stock into this equation and find out if it is a good choice for value-oriented investors right now.

  • 3 Best Biotech Acquisitions of 2018 (So Far)
    Motley Fool16 days ago

    3 Best Biotech Acquisitions of 2018 (So Far)

    There were bigger biotech deals than these this year, but arguably none better.

  • Reuters16 days ago

    Swiss bank Vontobel to cut up to 140 jobs at Notenstein La Roche

    ZURICH (Reuters) - Swiss private bank Vontobel (VONN.S) could cut up to a third of the workforce at Notenstein La Roche after it completed the takeover of its smaller rival. Vontobel could cut up to 140 ...

  • Roche's Breast Cancer Study Meets Co-Primary Endpoint
    Zacks18 days ago

    Roche's Breast Cancer Study Meets Co-Primary Endpoint

    Phase III IMpassion130 study shows that Roche???s (RHHBY) Tecentriq plus Abraxane significantly reduced the risk of disease worsening or death in people with metastatic triple negative breast cancer.